⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EVMN News
Evommune, Inc.
Form 8-K
sec.gov
EVMN
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
businesswire.com
EVMN
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
businesswire.com
EVMN
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
businesswire.com
EVMN
NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading USA - English APAC - English
prnewswire.com
EVMN
ARW